Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rationalisation of antipsychotic drug use in older people using [18F]-Fallypride PET
2011-005218-13Phase 4Terminated
- Sponsor
- King's College London
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of amisulpride in Alzheimer's disease (AD) and Schizophrenia Spectrum Disorders (SSD) (5 arms), sponsored by King's College London. Primary endpoint: Dopamine D2/3 receptor occupancy at steady state. Started Feb 2012; status: terminated.
02
Drugs
amisulpride
03
Conditions
Alzheimer's disease (AD)Schizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on 2011-005218-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005218-13.